# Multi-omics prediction of axillary treatment response and tumour microenvironment alterations in lymph node-positive luminal breast cancer

**Authors:** Teng Ma, Zirui Wang, Zhe Zhou, Yongmei Wang, Tianyi Ma, Xiangping Liu, Yan Mao, Haibo Wang

PMC · DOI: 10.1038/s41419-025-07877-6 · Cell Death & Disease · 2025-08-04

## TL;DR

This study develops a multi-omics model to predict treatment response in lymph node-positive breast cancer, potentially reducing unnecessary surgery.

## Contribution

A novel multi-omics model is introduced to predict pathological lymph node complete response after chemotherapy in luminal breast cancer.

## Key findings

- A multi-omic model with 12 radiomic and four clinicopathological features achieved 0.853 and 0.805 AUC in training and validation cohorts.
- Single-cell RNA sequencing revealed immunosuppressive features in patients with poor neoadjuvant chemotherapy response.
- The model could help reduce unnecessary axillary surgery by predicting treatment response in metastatic lymph nodes.

## Abstract

Luminal breast cancer (BC) with axillary lymph node (ALN) metastasis is typically treated with neoadjuvant chemotherapy (NAC). Theoretically, patients who achieve pathological lymph node complete response after NAC can be exempted from ALN dissection and even have the possibility of being spared axillary surgery. However, there is no effective way to preoperatively assess whether a metastatic ALN achieved pathological lymph node complete response (pLCR) after NAC. Therefore, we retrospectively collected imaging, clinical, and pathological data from two centres, built a multi-omic model to predict pLCR, and validated its accuracy and clinical applicability. We identified 12 radiomic and four clinicopathological features for model construction; the areas under the curve for training and validation cohorts were 0.853 and 0.805, respectively. Subsequently, single-cell RNA sequencing analysis was conducted on patients with different efficacy and its association with the tumour immune microenvironment was investigated. Eleven cell clusters in 14 samples from five patients were identified with differing NAC responses; comparative analysis indicated that those with poor responses had immunosuppressive features, which provided a theoretical basis for elucidating the resistance mechanism of NAC in axillary metastatic lymph nodes. The multi-omics prediction model demonstrated good performance in predicting ALN status after NAC, offering the possibility of reducing unnecessary axillary surgery.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** MARCO (macrophage receptor with collagenous structure) [NCBI Gene 8685] {aka SCARA2, SR-A6}, Cd3g (CD3 antigen, gamma polypeptide) [NCBI Gene 12502] {aka Ctg-3, Ctg3, T3g}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, CADM1 (cell adhesion molecule 1) [NCBI Gene 23705] {aka BL2, IGSF4, IGSF4A, NECL2, Necl-2, RA175}, CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283] {aka CMK, Humig, MIG, SCYB9, crg-10}, Dcn (decorin) [NCBI Gene 13179] {aka DC, DSPG2, PG40, PGII, PGS2, SLRR1B}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, Vwf (Von Willebrand factor) [NCBI Gene 22371] {aka 6820430P06Rik, B130011O06Rik, C630030D09, F8VWF, VWD}, NR4A2 (nuclear receptor subfamily 4 group A member 2) [NCBI Gene 4929] {aka HZF-3, IDLDP, NOT, NURR1, RNR1, TINUR}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, S100a8 (S100 calcium binding protein A8 (calgranulin A)) [NCBI Gene 20201] {aka 60B8Ag, B8Ag, CFAg, CP-10, Caga, MRP8}, Cdh5 (cadherin 5) [NCBI Gene 12562] {aka 7B4, Cd144, VE-Cad, VECD, VEcad, Vec}, Tpsab1 (tryptase alpha/beta 1) [NCBI Gene 100503895] {aka MMCP-7, Mcp-7, Mcp7, Mcpt7}, CXCL13 (C-X-C motif chemokine ligand 13) [NCBI Gene 10563] {aka ANGIE, ANGIE2, BCA-1, BCA1, BLC, BLR1L}, HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) [NCBI Gene 3119] {aka CELIAC1, HLA-DQB, IDDM1}, Tpsb2 (tryptase beta 2) [NCBI Gene 17229] {aka MMCP-6, Mcp-6, Mcp6, Mcpt6}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, Epcam (epithelial cell adhesion molecule) [NCBI Gene 17075] {aka CD326, EGP, EGP-2, Egp314, Ep-CAM, EpCAM1}, PVR (PVR cell adhesion molecule) [NCBI Gene 5817] {aka CD155, HVED, NECL5, Necl-5, PVS, TAGE4}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}, CXCL3 (C-X-C motif chemokine ligand 3) [NCBI Gene 2921] {aka CINC-2b, GRO3, GROg, MIP-2b, MIP2B, SCYB3}, IER2 (immediate early response 2) [NCBI Gene 9592] {aka CHX1, ETR101}, ZNF683 (zinc finger protein 683) [NCBI Gene 257101] {aka Hobit}, FOLR2 (folate receptor beta) [NCBI Gene 2350] {aka BETA-HFR, FBP, FBP/PL-1, FR-BETA, FR-P3, FRbeta}, Tagln (transgelin) [NCBI Gene 21345] {aka Sm22, Sm22a, Ws310}, S100a9 (S100 calcium binding protein A9 (calgranulin B)) [NCBI Gene 20202] {aka 60B8Ag, BEE22, Cagb, GAGB, L1Ag, MRP14}, Lyz1 (lysozyme 1) [NCBI Gene 17110] {aka Lyz, Lyzf3, Lzp-s}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, Mzb1 (marginal zone B and B1 cell-specific protein 1) [NCBI Gene 69816] {aka 2010001M09Rik, PACAP, pERp1}, Krt19 (keratin 19) [NCBI Gene 16669] {aka CK-19, EndoC, K19, Krt-1.19, Krt1-19}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, HLA-DRB5 (major histocompatibility complex, class II, DR beta 5) [NCBI Gene 3127] {aka DRB5, HLA-DRB5*}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, Col1a2 (collagen, type I, alpha 2) [NCBI Gene 12843] {aka Col1a-2, Cola-2, Cola2, oim}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, Cd19 (CD19 antigen) [NCBI Gene 12478], Il3ra (interleukin 3 receptor, alpha chain) [NCBI Gene 16188] {aka CD123, CDw123, SUT-1}, Cd3d (CD3 antigen, delta polypeptide) [NCBI Gene 12500] {aka T3d}, Krt18 (keratin 18) [NCBI Gene 16668] {aka CK18, K18, Krt1-18}, Igfbp7 (insulin-like growth factor binding protein 7) [NCBI Gene 29817] {aka AGM, Fstl2, Mac25}, RNASE1 (ribonuclease A family member 1, pancreatic) [NCBI Gene 6035] {aka RAC1, RIB1, RNS1}, Cd79a (CD79A antigen (immunoglobulin-associated alpha)) [NCBI Gene 12518] {aka Ig-alpha, Iga, Igalpha, Ly-54, Ly54, mb-1}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, Cd14 (CD14 antigen) [NCBI Gene 12475], LYVE1 (lymphatic vessel endothelial hyaluronan receptor 1) [NCBI Gene 10894] {aka CRSBP-1, HAR, LYVE-1, XLKD1}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, Cd3e (CD3 antigen, epsilon polypeptide) [NCBI Gene 12501] {aka CD3, CD3epsilon, T3e}, Col1a1 (collagen, type I, alpha 1) [NCBI Gene 12842] {aka Col1a-1, Cola-1, Cola1, Mov-13, Mov13}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}
- **Diseases:** Breast cancer (MESH:D001943), NAC (MESH:D000084202), ALN (MESH:D000072717), ITC (MESH:D018295), invasive (MESH:D009361), positive (MESH:D000377), Cytotoxicity (MESH:D064420), mastectomy (MESH:D000072656), pain (MESH:D010146), sensory dysfunction (MESH:D012678), nerve damage (MESH:D000080902), ALN metastases (MESH:D008207), necrotic (MESH:D009336), metastases (MESH:D009362), T (MESH:D001260), N (MESH:C536108), Tumour (MESH:D009369), pCR (MESH:D005598), inflammatory (MESH:D007249), breast lesion (MESH:D061325), fibrosis (MESH:D005355)
- **Chemicals:** DAPI (MESH:C007293), paraffin (MESH:D010232), Gd-DTPA (MESH:D019786), DCE (-), Formalin (MESH:D005557), taxane (MESH:C080625), anthracycline (MESH:D018943), tryptophan (MESH:D014364)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** T — Homo sapiens (Human), Esophageal squamous cell carcinoma, Cancer cell line (CVCL_3174)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12322124/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12322124/full.md

---
Source: https://tomesphere.com/paper/PMC12322124